GNCA.Q Overzicht aandelen
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 0/6 |
Genocea Biosciences, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$0.0001 |
| 52 Week Hoogtepunt | US$0.099 |
| 52 Week Laag | US$0.0001 |
| Bèta | 2.07 |
| 11 maand verandering | 0% |
| 3 maanden verandering | -66.67% |
| 1 Jaar Verandering | -99.84% |
| 33 jaar verandering | -100.00% |
| 5 jaar verandering | -100.00% |
| Verandering sinds IPO | -100.00% |
Recent nieuws en updates
Recent updates
Here's Why Shareholders May Want To Be Cautious With Increasing Genocea Biosciences, Inc.'s (NASDAQ:GNCA) CEO Pay Packet
Jun 17
What Type Of Returns Would Genocea Biosciences'(NASDAQ:GNCA) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Feb 18How Much Of Genocea Biosciences, Inc. (NASDAQ:GNCA) Do Institutions Own?
Jan 14
Rendement voor aandeelhouders
| GNCA.Q | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 0% | -0.7% | -1.6% |
| 1Y | -99.8% | 19.8% | 30.8% |
Rendement versus industrie: GNCA.Q underperformed the US Biotechs industry which returned -3.5% over the past year.
Rendement versus markt: GNCA.Q underperformed the US Market which returned 15.2% over the past year.
Prijsvolatiliteit
| GNCA.Q volatility | |
|---|---|
| GNCA.Q Average Weekly Movement | 1,251.8% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: GNCA.Q's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: GNCA.Q's weekly volatility has increased from 816% to 1252% over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2006 | 74 | Chip Clark | www.genocea.com |
Genocea Biosciences, Inc. Samenvatting
| GNCA.Q fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$5.88k |
| Inkomsten(TTM) | -US$37.19m |
| Inkomsten(TTM) | US$1.91m |
0.0x
P/S-verhouding0.0x
Koers/WinstverhoudingIs GNCA.Q overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| GNCA.Q resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$1.91m |
| Kosten van inkomsten | US$0 |
| Brutowinst | US$1.91m |
| Overige uitgaven | US$39.10m |
| Inkomsten | -US$37.19m |
Laatst gerapporteerde inkomsten
Mar 31, 2022
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.63 |
| Brutomarge | 100.00% |
| Nettowinstmarge | -1,946.15% |
| Schuld/Eigen Vermogen Verhouding | 61.7% |
Hoe presteerde GNCA.Q op de lange termijn?
Bekijk historische prestaties en vergelijking